Sézary Syndrome
📧 Sign up to get email alerts when something new happens for Sézary Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-09-04Clinical Trial Update: Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
Real-world observational study PROSPER evaluating mogamulizumab (Poteligeo) in adults with mycosis fungoides and Sézary syndrome; the study …
-
CLINICAL_TRIALS trial_result · 2024-08-30Clinical Trial Update: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) [Phase 2]
Phase 2 trial evaluating maintenance treatment with resminostat in patients with advanced mycosis fungoides or Sézary syndrome has completed…
-
FDA approval · 2024-08-07FDA Approved: LYMPHIR — Original Application (Citius Pharmaceuticals, Inc.)
FDA approved LYMPHIR (denileukin diftitox-CXDL) through an original application for the treatment of CD25-expressing cutaneous T-cell lympho…
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: VircapSeq Virus Detection in Sézary Syndrome
A completed study evaluated VircapSeq virus detection in patients with Sézary syndrome, a form of cutaneous T-cell lymphoma, with results po…
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL [Phase 3]
Phase 3 clinical trial of naloxone hydrochloride for relief of pruritus in patients with cutaneous T-cell lymphoma (Mycosis Fungoides and Sé…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-30Clinical Trial Update: Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma [Phase 2]
Phase 2 trial updates the combination of pembrolizumab and interferon-gamma for various mycosis fungoides/Sezary syndrome and synovial sarco…
-
FDA approval · 2022-04-27FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for BEXAROTENE from Amneal Pharmaceuticals NY LLC.
-
FDA approval · 2022-03-30FDA Approved: POTELIGEO — Supplemental Application (Kyowa Kirin, Inc.)
The FDA approved a supplemental application for POTELIGEO (mogamulizumab-kpkc) submitted by Kyowa Kirin, Inc.
-
FDA approval · 2021-03-19FDA Approved: UVADEX — Supplemental Application (Therakos LLC)
FDA approved a supplemental application for UVADEX (methoxsalen) from Therakos LLC.
-
FDA approval · 2021-01-14FDA Approved: BEXAROTENE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s original application for generic Bexarotene. The drug is indicated for the treatment of cutaneous T-cell…
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome [Phase 2]
Phase 2 trial update of lenalidomide in relapsed mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma) has completed; results posted…
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome [Phase 2]
A Phase 2 trial evaluating alemtuzumab in relapsed or refractory advanced mycosis fungoides or Sézary syndrome has completed.
-
FDA approval · 2018-12-11FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZOLINZA (vorinostat) from Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2018-11-16Clinical Trial Update: NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) [Phase 2]
Phase 2 trial update for NM-IL-12 in Cutaneous T-Cell Lymphoma undergoing total skin electron beam therapy (TSEBT).
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome [Phase 1]
Phase 1 trial investigating gemcitabine and pemetrexed disodium in advanced mycosis fungoides or Sézary syndrome (a form of cutaneous T-cell…
-
FDA approval · 2018-09-04FDA Approved: BEXAROTENE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's original-application generic of Bexarotene for cutaneous T-cell lymphoma.
-
FDA approval · 2018-08-08FDA Approved: POTELIGEO — Original Application (Kyowa Kirin, Inc.)
The FDA approved Poteligeo (mogamulizumab-kpkc) in the original BLA for adults with relapsed or refractory mycosis fungoides or Sézary syndr…
-
FDA approval · 2018-05-08FDA Approved: BEXAROTENE — Original Application (ANI Pharmaceuticals, Inc.)
ANI Pharmaceuticals received FDA approval for a generic bexarotene through an Original Application (ANDA). The product is indicated for the …
-
CLINICAL_TRIALS trial_result · 2017-05-10Clinical Trial Update: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome [Phase 4]
Phase 4 trial evaluating neurokinin-1 receptor antagonism to treat pruritus in patients with Sézary syndrome; the study was terminated and r…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) [Phase 2]
A Phase 2 clinical trial evaluating oral vorinostat (SAHA) for advanced cutaneous T-cell lymphoma, including Sézary syndrome and mycosis fun…
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma [Phase 2]
Phase 2 study update of the HDAC inhibitor quisinostat in previously treated Cutaneous T-Cell Lymphoma (Stage Ib-IVa) has completed.
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Effect of Denileukin Diftitox on Immune System in CTCL Patients
This completed trial update reports on the effects of denileukin diftitox on the immune system in patients with cutaneous T-cell lymphoma, i…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Immunization Against Tumor Cells in Sezary Syndrome [Phase 2]
Status update indicates the completion of a Phase 2 clinical trial evaluating an immunization against tumor cells in Sézary syndrome (cutane…
-
FDA approval · 2014-12-02FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for Targretin (bexarotene) submitted by Bausch Health US, LLC.
-
FDA approval · 2014-08-12FDA Approved: BEXAROTENE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's generic bexarotene for use in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome.